Applied Filters
McDermott hires Boston pair from Polsinelli
McDermott Will & Emery has strengthened its IP practice in Boston with the addition of Michael Siekman and Jenny Chen as partners.
Novavax partners with Takeda to deliver COVID-19 vaccine in Japan
US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.
LSPN Connect: micro-managing with Pendulum Therapeutics
With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.
KIPA hires former Decode Genetics director
IP boutique KIPA has strengthened its team with the addition of Iceland-based patent attorney Thorlakur Jonsson.
Children’s hospital researcher admits selling trade secrets to China
A former researcher at the research institute of the Nationwide Children’s Hospital in Ohio has pleaded guilty to conspiring to steal scientific trade secrets to sell in China.
LSPN Connect: CRISPR, IP headaches and ‘deplorable’ diversity
The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Roche stakes $2bn on UCB Alzheimer’s disease treatment
Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.
University can claim sovereign immunity in cancer treatment suit, rules Federal Circuit
The University of Texas is protected from being forced to become an involuntary plaintiff in an infringement suit because of sovereign immunity, the US Court of Appeals for the Federal Circuit ruled on Friday, July 24.
Gilead continues oncology expansion with Tizona deal
Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
PTAB blocks Qiagen’s bid to invalidate diagnostics patent
Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.
